Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12619000660189
Ethics application status
Approved
Date submitted
11/02/2019
Date registered
2/05/2019
Date last updated
27/08/2021
Date data sharing statement initially provided
2/05/2019
Type of registration
Prospectively registered
Titles & IDs
Public title
Topical Dorzolamide for Idiopathic Macular Hole
Query!
Scientific title
A randomised clinical trial, to evaluate the efficacy of topical dorzolamide for the treatment of idiopathic macular hole
Query!
Secondary ID [1]
297353
0
Nil known
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Idiopathic macular hole
311499
0
Query!
Condition category
Condition code
Eye
310134
310134
0
0
Query!
Diseases / disorders of the eye
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
In this double blinded study, those randomised to treatment will receive 2% dorzolamide drops to the eye three times per day for 8 weeks. Drops will be self administered by the patient following detailed instruction and will not be supervised.
Query!
Intervention code [1]
313616
0
Treatment: Drugs
Query!
Comparator / control treatment
Placebo, 0.9% saline drops
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
319027
0
Closure of macular hole as assessed with optical coherence tomography
Query!
Assessment method [1]
319027
0
Query!
Timepoint [1]
319027
0
8 weeks post initiation of treatment.
Query!
Secondary outcome [1]
366753
0
Visual acuity measured in letters using an ETDRS chart
Query!
Assessment method [1]
366753
0
Query!
Timepoint [1]
366753
0
8 weeks post initiation of treatment.
Query!
Secondary outcome [2]
366754
0
Central retinal thickness as assessed with optical coherence tomography
Query!
Assessment method [2]
366754
0
Query!
Timepoint [2]
366754
0
8 weeks post initiation of treatment.
Query!
Eligibility
Key inclusion criteria
Ability to provide informed consent and complete study assessments
Age 18 years or older
Idiopathic macular hole in study eye
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Renal impairment with creatinine clearance <30ml/min.
Other retinal pathology
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation concealment using identical appearing numbered dropper bottles
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
The number needed to detect a difference of 50% magnitude in difference in hole closure is 13 subjects in each arm (power of 80% and confidence interval of 95%). Assuming a rate of non-closure in observation group to be 6% and rate of non-closure in CAI treated group to be 50%, the number needed to treat would be 2.3 patients.
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
13/05/2019
Query!
Actual
28/02/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
26
Query!
Accrual to date
10
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Recruitment hospital [1]
13088
0
The Royal Adelaide Hospital - Adelaide
Query!
Recruitment postcode(s) [1]
25597
0
5000 - Adelaide
Query!
Funding & Sponsors
Funding source category [1]
301918
0
Hospital
Query!
Name [1]
301918
0
Royal Adelaide Hospital
Query!
Address [1]
301918
0
Port Road, Adelaide SA 5000
Query!
Country [1]
301918
0
Australia
Query!
Primary sponsor type
Other Collaborative groups
Query!
Name
South Australian Institute of Ophthalmology
Query!
Address
6G Ophthalmology
The Royal Adelaide Hospital
1 Port Rd, Adelaide SA 5000
Query!
Country
Australia
Query!
Secondary sponsor category [1]
301673
0
None
Query!
Name [1]
301673
0
Query!
Address [1]
301673
0
Query!
Country [1]
301673
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
302603
0
CALHN Human Research Ethics Committee
Query!
Ethics committee address [1]
302603
0
CALHN Research Office RAH Clinical Trial Centre Wayfinder 3D460.02 Level 3, Royal Adelaide Hospital Port Road ADELAIDE SA 5000
Query!
Ethics committee country [1]
302603
0
Australia
Query!
Date submitted for ethics approval [1]
302603
0
17/04/2019
Query!
Approval date [1]
302603
0
06/05/2019
Query!
Ethics approval number [1]
302603
0
R20190214
Query!
Summary
Brief summary
This randomised controlled trial will assess the efficacy of topical dorzolamide achieving macular hole closure prior to vitreoretinal surgery.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
90790
0
Dr Weng Onn Chan
Query!
Address
90790
0
6G Ophthalmology
The Royal Adelaide Hospital
1 Port Rd, Adelaide SA 5000
Query!
Country
90790
0
Australia
Query!
Phone
90790
0
+61 8 70740000
Query!
Fax
90790
0
Query!
Email
90790
0
[email protected]
Query!
Contact person for public queries
Name
90791
0
Weng Onn Chan
Query!
Address
90791
0
6G Ophthalmology
The Royal Adelaide Hospital
1 Port Rd, Adelaide SA 5000
Query!
Country
90791
0
Australia
Query!
Phone
90791
0
+61 8 70740000
Query!
Fax
90791
0
Query!
Email
90791
0
[email protected]
Query!
Contact person for scientific queries
Name
90792
0
Weng Onn Chan
Query!
Address
90792
0
6G Ophthalmology
The Royal Adelaide Hospital
1 Port Rd, Adelaide SA 5000
Query!
Country
90792
0
Australia
Query!
Phone
90792
0
+61 8 70740000
Query!
Fax
90792
0
Query!
Email
90792
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
This data will not be disclosed as per the ethics applicition.
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF